CTT Systems AB
14.12.2021 13:16:37 CET | ACCESS Newswire | Press release
NYKÖPING, SE / ACCESSWIRE / December 14, 2021 / CTT Systems AB (STO:CTT)
CTT SYSTEMS AB ("CTT"), the market leader of aircraft humidity control system, announces Inflight Humidification ("IFH") VIP system order from AMAC Aerospace for one Boeing BBJMAX8 aircraft. The IFH VIP system is designed to increase humidity in the entire aircraft cabin, which requires support from three humidifiers. The BBJMAX8 aircraft will be moisture protected with CTT's unique Anti-Fuselage-Condensation technology. The system is scheduled to be delivered to AMAC in Q2 2022. Based on list price, the order value is 4 MSEK. This is CTT Systems' 97th Inflight Humidification award for VIP aircraft (from Airbus ACJ and Boeing BBJ).
"We look forward to work together with CTT once again in a VIP completion project. Cabin humidification is a common request from our VIP clients that value good health, wellbeing and feeling at ease during and after flight," comments Tracey Hawthorne-Kurz, Director Logistics & Purchasing at AMAC Aerospace Switzerland.
"We are pleased to cooperate with AMAC Aerospace in fitting in our IFH system in another BBJMAX VIP completion," says Peter Landquist, Vice President Sales & Marketing at CTT Systems.
About humidification on VIP and large-cabin business jets
Without an efficient humidification system, the cabin air in the VIP aircraft or large, cabin business jet is far more dehydrating than any place on Earth - below 5 % Relative Humidity (RH). This Boeing BBJMAX8 will have a striking humidity increase, restored to comfort and wellbeing level, to approx. 20 % RH. VIP passengers will on long-haul flights benefit from reduced dry air related problems (read: fatigue, jet-lag, red eyes, dry throat, dry skin, spread of virus diseases) and improved wellbeing and general sleep. The CTT humidifier is based on evaporative cooling technology and uses a method that effectively precludes the transfer of bacteria. The CTT IFH VIP system offers total anti-condensation protection.
About AMAC
AMAC Aerospace is offering narrow and wide-body VIP Completion and Maintenance for the corporate/private aviation market. The company was founded in 2007 in Basel, Switzerland. Today the company is the largest privately-owned facility in the world and led by Kadri Muhiddin, Executive Chairman/Group CEO, Bernd Schramm, Group COO and Mauro Grossi, Group CFO. The successful progress attests to the commitment to excellence. With long-term industry engagement, deep industry roots, extensive experience and strong international network, the AMAC team collaborates to exceed the expectations of clients, airworthiness authorities and original equipment manufacturers. www.amacaerospace.com
For additional information about AMAC Aerospace: Ms. Jacqueline Etter, +41 58 310 3594 or email: Jacqueline.etter@amacaerospace.com
For additional information:
Peter Landquist, VP Senior Advisor Sales, CTT Systems AB.
Tel. 0155-20 59 02 alt. Mobile. 070-665 24 45 or email: peter.landquist@ctt.se
Ola Häggfeldt, Sales Director, CTT Systems AB.
Tel. 0155-20 59 30 or email: ola.haggfeldt@ctt.se
About CTT Systems
CTT is the leading supplier of active humidity control systems in aircraft. We solve the aircraft humidity paradox - with far too dry cabin air - and too much moisture in the fuselage - causing dehydration for people onboard and excess weight in the aircraft inducing larger environmental footprint. CTT offers humidifiers and dehumidifiers available for retrofit and line-fit on commercial aircraft as well as private jets. For more information about CTT and how active humidity control products make air traveling a little more sustainable and far more pleasurable, please visit: www.ctt.se
Attachments
SOURCE: CTT Systems AB
View source version on accesswire.com:
https://www.accesswire.com/677526/CTT-Systems-Receives-Inflight-Humidification-VIP-System-Order-for-One-Boeing-BBJMAX8-Aircraft-from-AMAC-Aerospace
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release
HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy
Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen
Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom